Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

subsequent autologous stem cell transplantation. Intermediate- or high-risk patients will be referred for allogeneic stem cell transplantation, if they have a matched donor. Until transplantation

ara-c
cell transplantation
myelodysplastic syndromes
remission
secondary acute myeloid leukemia
  • 32 views
  • 07 Oct, 2021
  • 10 locations
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

having progressed within one 18 months of initial treatment including autologous stem cell transplantation (ASCT) (Cohort 2a), and without ASCT (Cohort 2b) or, in subjects with inadequate response post

measurable disease
proteasome inhibitor
cell transplantation
refractory multiple myeloma
serum proteins
  • 12 views
  • 09 Sep, 2021
  • 27 locations
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or are just

whole-brain radiotherapy
rituximab
nervous
cancer
methotrexate
  • 0 views
  • 13 May, 2022
  • 35 locations
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells …

cell transplantation
cytarabine
vincristine
mantle cell lymphoma
r-chop
  • 367 views
  • 31 Jan, 2022
  • 238 locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified > 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete …

etoposide
dinutuximab
mycn protein
topotecan
vincristine
  • 308 views
  • 26 Jan, 2021
  • 126 locations
MInimal Residual Disease Adapted Strategy (MIDAS)

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined …

  • 0 views
  • 26 Apr, 2022
  • 32 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking …

etoposide
dinutuximab
shortening fraction
mycn protein
topotecan
  • 117 views
  • 06 Jun, 2022
  • 95 locations
Autologous Stem Cell Transplantation for Crohn's Disease

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.

mesalamine
platelet count
certolizumab pegol
adalimumab
natalizumab
  • 168 views
  • 21 Mar, 2022
  • 2 locations
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis (SSc)

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

total body irradiation
mesna
rituximab
MRSS
cyclophosphamide
  • 200 views
  • 24 Mar, 2022
  • 2 locations
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and …

measurable disease
cell transplantation
chemotherapy regimen
monoclonal protein
bortezomib
  • 0 views
  • 26 Jan, 2022
  • 1 location